Strategic partnerships Serametrix collaborates with high-profile cancer research institutions such as LICR and MSK, indicating openness to co-development and sponsored studies. Leverage these relationships to position joint-venture opportunities, larger contract research engagements, and expanded immune monitoring services for multi-center trials.

Immune monitoring focus Specialization in monitoring anti-tumor immunity and analysis of myeloid-derived suppressor cells suggests a strong demand for specialized immunoassays in oncology trials. Pitch expanded panels, assay validation services, and data analytics packages to sponsors seeking deeper immune correlates.

Market positioning Acquired by Caprion Biosciences in 2019 and co-owned with LICR position Serametrix within a network of established CRO capabilities. Target enterprise clients looking for integrated immune monitoring solutions within broader trial operations and translational research offerings.

Global trial readiness With a lean team (11-50 employees) and expertise in standardizing academic technologies for clinical use, Serametrix may enable scalable, cost-efficient immune monitoring for mid- to late-phase oncology programs. Propose scalable service packages and tiered pricing for expanding trials.

Technology and data Utilizes familiar web tech stack and focuses on delivering actionable immune data. Offer value-driven data delivery enhancements, secure data integration with client systems, and analytics dashboards to help sponsors meet regulatory and publication needs.